Nanotechnology and the treatment of HIV infection

Viruses

Volumn 4, Issue 4, 2012, Pages 488-520

  Parboosing, Raveen ^a   Maguire, Glenn E M ^b   Govender, Patrick ^b   Kruger, Hendrik G ^b  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Antiretroviral agents; HIV; Nanomedicine; Nanoparticles; Nanotechnology

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; ATAZANAVIR; BRYOSTATIN 2; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DENDRIMER; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; FULLERENE; INDINAVIR; LAMIVUDINE; LIPOSOME; MACROGOL; NANOCAPSULE; NANOCARRIER; NANOCRYSTAL; NANOPARTICLE; NELFINAVIR; NEVIRAPINE; QUANTUM DOT; RIBOZYME; RILPIVIRINE; SAQUINAVIR; SDC 1721; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; ZIDOVUDINE 5' TRIPHOSPHATE;

BIOMIMETICS; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONJUGATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG COATING; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG TARGETING; ENCAPSULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV 1 ENCEPHALITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNALIZATION; LATENT VIRUS INFECTION; MACROPHAGE; MICELLE; NANOMEDICINE; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; OPSONIZATION; PARTICLE SIZE; PHAGOCYTOSIS; RETICULOENDOTHELIAL SYSTEM; REVIEW; SURFACE CHARGE; SURFACE PROPERTY; VIRUS ENCEPHALITIS; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG CARRIERS; HIV INFECTIONS; HUMANS; NANOSTRUCTURES; NANOTECHNOLOGY;

EID: 84860244308     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v4040488     Document Type: Review

References (194)

1. Picraux, T. Nanotechnology. In Encyclopaedia Britannica Deluxe Edition; Encyclopaedia Britannica: Chicago, IL, USA, 2010.
2. Goldberg, M.; Langer, R.; Xinqiao, J. Nanostructured materials for applications in drug delivery and tissue engineering. J. Biomat. Sci. Polym. E 2007, 18, 241-268.
3. Tegart, G. Nanotechnology: The technology for the 21st Century. In Proceedings of the Second International Conference on Technology Foresight; APEC Center for Technology Foresight, Bangkok, Thailand, 27-28 February 2001.
4. McNeil, S.E. Unique benefits of nanotechnology to drug delivery and diagnostics. Methods Mol. Biol. 2011, 697, 3-8.
5. Ochekpe, N.A.; Olorunfemi, P.O.; Ngwuluka, N.C. Nanotechnology and drug delivery part 1: Background and applications. Trop. J. Pharm. Res. 2009, 8, 265-274.
6. Williams, D. The relationship between biomaterials and nanotechnology. Biomaterials 2008, 29, 1737-1738.
7. Sanvicens, N.; Marco, M.P. Multifunctional nanoparticles-Properties and prospects for their use in human medicine. Trends Biotechnol. 2008, 26, 425-433.
8. United States National Nanotechnology Initiative. Nanotechnology 101: What is it and how it works. Available online: http://www.nano.gov/nanotech-101/what (accessed on 5 December 2011).
9. Fields, B.N.; Knipe, D.M.; Howley, P.M. Fields' Virology, 5th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007.
10. Braunwald, E.; Hauser, S.L.; Fauci, A.S.; Longo, D.L.; Kasper, D.L.; Jameson, J.L. Harrison's Principles of Internal Medicine, 15th ed.; McGraw-Hill: New York, NY, USA, 2001.
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. United States Department of Health and Human Services Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available online: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed on 9 March 2012).
12. Clarke, J.R.; White, N.C.; Weber, J.N. HIV compartmentalization: Pathogenesis and clinical implications. AIDS Rev. 2000, 2, 15-22.
13. Stevenson, M. HIV-1 pathogenesis. Nat. Med. 2003, 9, 853-860.
14. Sonza, S.; Crowe, S.M. Reservoirs for HIV infection and their persistence in the face of undetectable viral load. AIDS Patient Care STDS 2001, 15, 511-518.
15. Crowe, S.M. Macrophages and residual HIV infection. Curr. Opin. HIV AIDS 2006, 1, 129.
16. Pomerantz, R. Reservoirs, sanctuaries, and residual disease: The hiding spots of HIV-1. HIV Clin. Trials 2003, 4, 137-143.
17. Palmer, S.; Josefsson, L.; Coffin, J.M. HIV reservoirs and the possibility of a cure for HIV infection. J. Intern. Med. 2011, 270, 550-560.
18. Dahl, V.; Josefsson, L.; Palmer, S. HIV reservoirs, latency, and reactivation: Prospects for eradication. Antivir. Res. 2010, 85, 286-294.
19. Farokhzad, O.C. Nanotechnology for drug delivery: The perfect partnership. Expert Opin. Drug Del. 2008, 5, 927-929.
20. Farokhzad, O.C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3, 16-20.
21. Petros, R.A.; DeSimone, J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9, 615-627.
22. Kinman, L.; Brodie, S.J.; Tsai, C.C.; Bui, T.; Larsen, K.; Schmidt, A.; Anderson, D.; Morton, W.R.; Hu, S.L.; Ho, R.J. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: A proof of concept study in HIV-2287-infected macaques. J. Acquir. Immune Defic. Syndr. 2003, 34, 387-397.
23. Kinman, L.; Bui, T.; Larsen, K.; Tsai, C.C.; Anderson, D.; Morton, W.R.; Hu, S.L.; Ho, R.J. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J. Acquir. Immune Defic. Syndr. 2006, 42, 155-161.
24. Choi, S.U.; Bui, T.; Ho, R.J. A pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J. Pharm. Sci. 2008, 97, 931-943.
25. Phillips, N.C.; Tsoukas, C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 1992, 79, 1137-1143.
26. Harvie, P.; Desormeaux, A.; Gagne, N.; Tremblay, M.; Poulin, L.; Beauchamp, D.; Bergeron, M.G. Lymphoid tissues targeting of liposome-encapsulated 2',3'-dideoxyinosine. AIDS 1995, 9, 701-707.
27. Désormeaux, A.; Harvie, P.; Perron, S.; Makabi-Panzu, B.; Beauchamp, D.; Tremblay, M.; Poulin, L.; Bergeron, M.G. Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2', 3'-dideoxyinosine. AIDS 1994, 8, 1545.
28. Sharma, P.; Garg, S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv. Drug Deliv. Rev. 2010, 62, 491-502.
29. Merisko-Liversidge, E.; Liversidge, G.G.; Cooper, E.R. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18, 113-120.
30. Junghanns, J.U.A.H.; Müller, R.H. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed. 2008, 3, 295-309.
31. Müller, R.H.; Gohla, S.; Keck, C.M. State of the art of nanocrystals - Special features, production, nanotoxicology aspects and intracellular delivery. Eur. J. Pharm. Biopharm. 2011, 78, 1-9.
32. Rabinow, B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 2004, 3, 785-796.
33. Baert, L.; Klooster, G.; Dries, W.; Francois, M.; Wouters, A.; Basstanie, E.; Iterbeke, K.; Stappers, F.; Stevens, P.; Schueller, L. et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 2009, 72, 502-508.
34. Klooster, G.; Hoeben, E.; Borghys, H.; Looszova, A.; Bouche, M.P.; van Velsen, F.; Baert, L. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 2010, 54, 2042-2050.
35. Caron, J.; Reddy, L.H.; Lepetre-Mouelhi, S.; Wack, S.; Clayette, P.; Rogez-Kreuz, C.; Yousfi, R.; Couvreur, P.; Desmaele, D. Squalenoyl nucleoside monophosphate nanoassemblies: New prodrug strategy for the delivery of nucleotide analogues. Bioorg. Med. Chem. Lett. 2010, 20, 2761-2764.
36. Fattal, E.; Barratt, G. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Brit. J. Pharmacol. 2009, 157, 179-194.
37. Howard, K.A. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug Deliv. Rev. 2009, 61, 710-720.
38. Singha, K.; Namgung, R.; Kim, W.J. Polymers in small-interfering RNA delivery. Nucleic Acid Ther. 2011, 21, 133-147.
39. Gao, K.; Huang, L. Nonviral methods for siRNA delivery. Mol. Pharm. 2009, 6, 651-658.
40. Zhang, S.; Zhao, B.; Jiang, H.; Wang, B.; Ma, B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Control. Release 2007, 123, 1-10.
41. de Martimprey, H.; Vauthier, C.; Malvy, C.; Couvreur, P. Polymer nanocarriers for the delivery of small fragments of nucleic acids: Oligonucleotides and siRNA. Eur. J. Pharm. Biopharm. 2009, 71, 490-504.
42. Luo, D.; Saltzman, W.M. Synthetic DNA delivery systems. Nat. Biotech. 2000, 18, 33-37.
43. Kayser, O.; Lemke, A.; Hernandez-Trejo, N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr. Pharm. Biotechno. 2005, 6, 3-5.
44. Gupta, U.; Jain, N.K. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv. Drug Deliv. Rev. 2010, 62, 478-490.
45. Chiappetta, D.A.; Facorro, G.; de Celis, E.R.; Sosnik, A. Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. Nanomedicine 2011, 7, 624-637.
46. Chiappetta, D.A.; Hocht, C.; Sosnik, A. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. Curr. HIV Res. 2010, 8, 223-231.
47. Chiappetta, D.A.; Hocht, C.; Taira, C.; Sosnik, A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. Nanomedicine (Lond.) 2010, 5, 11-23.
48. Chiappetta, D.A.; Hocht, C.; Taira, C.; Sosnik, A. Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. Biomaterials 2011, 32, 2379-2387.
49. Chiappetta, D.A.; Sosnik, A. Poly (ethylene oxide)-poly (propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs. Eur. J. Pharm. Biopharm. 2007, 66, 303-317.
50. Hillaireau, H.; Le Doan, T.; Appel, M.; Couvreur, P. Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. J. Control. Release 2006, 116, 346-352.
51. Hillaireau, H.; Le Doan, T.; Besnard, M.; Chacun, H.; Janin, J.; Couvreur, P. Encapsulation of antiviral nucleotide analogues azidothymidine-triphosphate and cidofovir in poly(isobutylcyanoacrylate) nanocapsules. Int. J. Pharm. 2006, 324, 37-42.
52. Muthu, M.S.; Singh, S. Targeted nanomedicines: Effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine (Lond.) 2009, 4, 105-118.
53. Garg, M.; Asthana, A.; Agashe, H.B.; Agrawal, G.P.; Jain, N.K. Stavudine loaded mannosylated liposomes: In vitro anti HIV I activity, tissue distribution and pharmacokinetics. J. Pharm. Pharmacol. 2006, 58, 605-616.
54. Garg, M.; Dutta, T.; Jain, N.K. Reduced hepatic toxicity, enhanced cellular uptake and altered pharmacokinetics of stavudine loaded galactosylated liposomes. Eur. J. Pharm. Biopharm. 2007, 67, 76-85.
55. Garg, M.; Garg, B.R.; Jain, S.; Mishra, P.; Sharma, R.K.; Mishra, A.K.; Dutta, T.; Jain, N.K. Radiolabeling, pharmacoscintigraphic evaluation and antiretroviral efficacy of stavudine loaded 99mTc labeled galactosylated liposomes. Eur. J. Pharm. Sci. 2008, 33, 271-281.
56. Wu, H.B.; Deng, Y.H.; Wang, S.N.; Zhou, X.Y.; Wang, N.; Shi, L. The distribution of azidothymidine palmitate galactosylated liposomes in mice. Yao Xue Xue Bao 2007, 42, 538-544.
57. Harvie, P.; Desormeaux, A.; Bergeron, M.C.; Tremblay, M.; Beauchamp, D.; Poulin, L.; Bergeron, M.G. Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosine. Antimicrob. Agents Ch. 1996, 40, 225-229.
58. Heiati, H.; Tawashi, R.; Phillips, N.C. Solid lipid nanoparticles as drug carriers: II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3'-azido-3'-deoxythymidine palmitate in mice. Int. J. Pharm. 1998, 174, 71-80.
59. Heiati, H.; Tawashi, R.; Shivers, R.R.; Phillips, N.C. Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 3'-azido-3'-deoxythymidine palmitate. Int. J. Pharm. 1997, 146, 123-131.
60. Kovochich, M.; Marsden, M.D.; Zack, J.A. Activation of latent HIV using drug-loaded nanoparticles. PLoS One 2011, 6, e18270.
61. Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5, 505-515.
62. Wan, L.; Zhang, X.; Gunaseelan, S.; Pooyan, S.; Debrah, O.; Leibowitz, M.J.; Rabson, A.B.; Stein, S.; Sinko, P.J., Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. AIDS Res. Ther. 2006, 3, 12.
63. Bowman, M.C.; Ballard, T.E.; Ackerson, C.J.; Feldheim, D.L.; Margolis, D.M.; Melander, C. Inhibition of HIV fusion with multivalent gold nanoparticles. J. Am. Chem. Soc. 2008, 130, 6896-6897.
64. Esté, J.A.; Cihlar, T. Current status and challenges of antiretroviral research and therapy. Antivir. Res. 2010, 85, 25-33.
65. Marsden, M.D.; Zack, J.A. Eradication of HIV: Current challenges and new directions. J. Antimicrob. Chemother. 2009, 63, 7-10.
66. Ma, X.; Wang, D.; Wu, Y.; Ho, R.J.; Jia, L.; Guo, P.; Hu, L.; Xing, G.; Zeng, Y.; Liang, X.J. AIDS treatment with novel anti-HIV compounds improved by nanotechnology. AAPS J. 2010, 12, 272-278.
67. Amiji, M.; Vyas, T.; Shah, L. Role of nanotechnology in HIV/AIDS treatment: Potential to overcome the viral reservoir challenge. Discov. Med. 2006, 6, 157-162.
68. NICNAS NICNAS Information Sheet Nanomaterials. Available online: http://www.nicnas.gov.au/publications/information_sheets/general_information_sheets/nis_nanomaterials_pdf.pdf (accessed on 1 December 2011).
69. Lines, M. Nanomaterials for practical functional uses. J. Alloy Compd. 2008, 449, 242-245.
70. Aitken, R.; Chaudhry, M.; Boxall, A.; Hull, M. Manufacture and use of nanomaterials: Current status in the UK and global trends. Occup. Med. 2006, 56, 300-306.
71. Niemeyer, C.; Mirkin, C. Nanobiotechnology: Concepts, Applications and Perspectives; Wiley- VCH: Weinheim, Germany, 2004.
72. Medepalli, K.K. Advanced Nanomaterials for Biomedical Applications; ProQuest: Cambridge, UK, 2008.
73. Schulz, M.J.; Shanov, V.N. Nanomedicine Design of Particles, Sensors, Motors, Implants, Robots, and Devices; Artech House Publishers: Boston, MA, USA, 2009.
74. Bawarski, W.E.; Chidlowsky, E.; Bharali, D.J.; Mousa, S.A. Emerging nanopharmaceuticals. Nanomedicine 2008, 4, 273-282.
75. Gunaseelan, S.; Gunaseelan, K.; Deshmukh, M.; Zhang, X.; Sinko, P.J. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv. Drug Deliv. Rev. 2010, 62, 518-531.
76. Nowacek, A.; Gendelman, H.E. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine 2009, 4, 557-574.
77. Mallipeddi, R.; Rohan, L.C. Progress in antiretroviral drug delivery using nanotechnology. Int. J. Nanomedicine 2010, 5, 533-547.
78. Ojewole, E.; Mackraj, I.; Naidoo, P.; Govender, T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur. J. Pharm. Biopharm. 2008, 70, 697-710.
79. Sosnik, A.; Chiappetta, D.A.; Carcaboso, Á.M. Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing ahead. J. Contr. Release 2009, 138, 2-15.
80. Wong, H.L.; Chattopadhyay, N.; Wu, X.Y.; Bendayan, R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug Deliver. Rev. 2010, 62, 503-517.
81. Govender, T.; Ojewole, E.; Naidoo, P.; Mackraj, I. Polymeric nanoparticles for enhancing antiretroviral drug therapy. Drug. Deliv. 2008, 15, 493-501.
82. Kim, P.S.; Read, S.W. Nanotechnology and HIV: Potential applications for treatment and prevention. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2, 693-702.
83. Mamo, T.; Moseman, E.A.; Kolishetti, N.; Salvador-Morales, C.; Shi, J.; Kuritzkes, D.R.; Langer, R.; von Andrian, U.; Farokhzad, O.C. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine 2010, 5, 269-285.
84. Neves, J.; Amiji, M.M.; Bahia, M.F.; Sarmento, B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv. Drug Deliv. Rev. 2010, 62, 458-477.
85. Fischer, H.C.; Chan, W.C.W. Nanotoxicity: The growing need for in vivo study. Curr. Opin. Biotech. 2007, 18, 565-571.
86. Ferrari, M. Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 2005, 5, 161-171.
87. Duncan, R.; Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011, 8, 2101-2141.
88. Sanhai, W.R.; Sakamoto, J.H.; Canady, R.; Ferrari, M. Seven challenges for nanomedicine. Nat. Nanotechnol. 2008, 3, 242-244.
89. Karmali, P.P.; Simberg, D. Interactions of nanoparticles with plasma proteins: Implication on clearance and toxicity of drug delivery systems. Expert Opin. Drug Del. 2011, 1-15.
90. Aggarwal, P.; Hall, J.B.; McLeland, C.B.; Dobrovolskaia, M.A.; McNeil, S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 2009, 61, 428-437.
91. Nie, S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond.) 2010, 5, 523.
92. Chrastina, A.; Massey, K.A.; Schnitzer, J.E. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2011, 3, 421-437.
93. He, C.; Hu, Y.; Yin, L.; Tang, C.; Yin, C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31, 3657-3666.
94. Spitzenberger, T.J.; Heilman, D.; Diekmann, C.; Batrakova, E.V.; Kabanov, A.V.; Gendelman, H.E.; Elmquist, W.F.; Persidsky, Y. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J. Cereb. Blood Flow Metab. 2007, 27, 1033-1042.
95. Pereira Oliveira, M.; Garcion, E.; Venisse, N.; Benoit, J.P.; Couet, W.; Olivier, J.C. Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice. Pharm. Res. 2005, 22, 1898-1905.
96. Koo, O.M.; Rubinstein, I.; Onyuksel, H. Role of nanotechnology in targeted drug delivery and imaging: A concise review. Nanomedicine 2005, 1, 193-212.
97. Vyas, T.K.; Shah, L.; Amiji, M.M. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin. Drug Deliv. 2006, 3, 613-628.
98. Shegokar, R.; Singh, K.K. Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation. Int. J. Pharm. 2011, 421, 341-352.
99. Kaur, A.; Jain, S.; Tiwary, A.K. Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation. Acta Pharm. 2008, 58, 61-74.
100. Gagné, J.F.; Désormeaux, A.; Perron, S.; Tremblay, M.J.; Bergeron, M.G. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim. Biophys. Acta 2002, 1558, 198-210.
101. Garg, M.; Dutta, T.; Jain, N.K. Stability study of stavudine-loaded O-palmitoyl-anchored carbohydrate-coated liposomes. AAPS PharmSciTech 2007, 8, 86-93.
102. Dutta, T.; Jain, N.K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. BBA Gen. Subjects 2007, 1770, 681-686.
103. Flasher, D.; Konopka, K.; Chamow, S.M.; Dazin, P.; Ashkenazi, A.; Pretzer, E.; Duzgunes, N. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). Biochim. Biophys. Acta 1994, 1194, 185-196.
104. Pollock, S.; Dwek, R.A.; Burton, D.R.; Zitzmann, N. N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. AIDS 2008, 22, 1961-1969.
105. Clayton, R.; Ohagen, A.; Nicol, F.; Vecchio, A.M.; Jonckers, T.H.; Goethals, O.; Van Loock, M.; Michiels, L.; Grigsby, J.; Xu, Z. et al. Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. Antivir. Res. 2009, 84, 142-149.
106. Dutta, T.; Agashe, H.B.; Garg, M.; Balasubramanium, P.; Kabra, M.; Jain, N.K. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target. 2007, 15, 89-98.
107. Dutta, T.; Garg, M.; Jain, N.K. Targeting of efavirenz loaded tuftsin conjugated poly (propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur. J. Pharm. Sci. 2008, 34, 181-189.
108. Harvie, P.; Désormeaux, A.; Gagné, N.; Tremblay, M.; Poulin, L.; Beauchamp, D.; Bergeron, M.G. Lymphoid tissues targeting of liposome-encapsulated 2',3'-dideoxyinosine. AIDS 1995, 9, 701-707.
109. Kroto, H.W.; Walton, D.R.M. Fullerene. In Encyclopaedia Britannica Deluxe Edition; Encyclopaedia Britannica: Chicago, IL, USA, 2010.
110. Pedziwiatr-Werbicka, E.; Ferenc, M.; Zaborski, M.; Gabara, B.; Klajnert, B.; Bryszewska, M. Characterization of complexes formed by polypropylene imine dendrimers and anti-HIV oligonucleotides. Colloid. Surface. B 2011, 83, 360-366.
111. Lee, C.C.; MacKay, J.A.; Fréchet, J.M.J.; Szoka, F.C. Designing dendrimers for biological applications. Nat. Biotechnol. 2005, 23, 1517-1526.
112. Chrai, S.S.; Murari, R.; Ahmad, I. Liposomes: A review. Pharmaceut. Tech. 2002, 26, 28-34.
113. Kwon, G.S.; Forrest, M.L. Amphiphilic block copolymer micelles for nanoscale drug delivery. Drug Develop. Res. 2006, 67, 15-22.
114. Croy, S.; Kwon, G. Polymeric micelles for drug delivery. Curr. Pharm. Design 2006, 12, 4669-4684.
115. Zhang, J.; Li, S.; Li, X. Polymeric nano-assemblies as emerging delivery carriers for therapeutic applications: A review of recent patents. Recent Pat. Nanotechnol. 2009, 3, 225-231.
116. Bekkara-Aounallah, F.; Gref, R.; Othman, M.; Reddy, L.H.; Pili, B.; Allain, V.; Bourgaux, C.; Hillaireau, H.; Lepêtre-Mouelhi, S.; Desmaële, D. et al. Novel PEGylated Nanoassemblies Made of Self-Assembled Squalenoyl Nucleoside Analogues. Adv. Funct. Mater. 2008, 18, 3715-3725.
117. Couvreur, P.; Stella, B.; Reddy, L.H.; Hillaireau, H.; Dubernet, C.; Desmaele, D.; Lepetre-Mouelhi, S.; Rocco, F.; Dereuddre-Bosquet, N.; Clayette, P. et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 2006, 6, 2544-2548.
118. Mason, T.G.; Wilking, J.; Meleson, K.; Chang, C.; Graves, S. Nanoemulsions: Formation, structure, and physical properties. J. Phys. Condens. Mat. 2006, 18, R635-R666.
119. AZoNano. Nanocapsules and Dendrimers-Properties and Future Applications. Available online: http://www.azonano.com/article.aspx?ArticleID=1649 (accessed on 2 December 2011)
120. Torchilin, V.P. Nanoparticulates as Drug Carriers; Imperial College Press; Distributed by World Scientific Pub.: London, UK/Hackensack, NJ, USA, 2006; pp. 29, 724.
121. British Standards Institution Vocabulary: Nanoparticles. Available online: http://www.bsigroup.com/sectorsandservices/Forms/PAS-712011-Download/ (accessed on 6 December 2011)
122. Bawa, R. Nanopharmaceuticals: Nanopharmaceuticals. European Journal of Nanomedicine 2010, 3, 34-40.
123. Fu, A.; Gu, W.; Boussert, B.; Koski, K.; Gerion, D.; Manna, L.; Gros, M.; Larabell, C.A.; Alivisatos, A.P. Semiconductor quantum rods as single molecule fluorescent biological labels. Nano Lett. 2006, 7, 179-182.
124. Buhro, W.E.; Colvin, V.L. Shape matters. Nat. Mater. 2003, 2, 138-139.
125. Wissing, S.; Kayser, O.; Muller, R. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56, 1257-1272.
126. Pozniak, A.L.; Morales-Ramirez, J.; Katabira, E.; Steyn, D.; Lupo, S.H.; Santoscoy, M.; Grinsztejn, B.; Ruxrungtham, K.; Rimsky, L.T.; Vanveggel, S. et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: Week 96 results of a phase IIb randomized trial. AIDS 2010, 24, 55-65.
127. Schrijvers, R.; Desimmie, B.A.; Debyser, Z. Rilpivirine: A step forward in tailored HIV treatment. Lancet 2011, 378, 201-203.
128. Kiser, J.J. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV. Curr. Opin. HIV AIDS 2008, 3, 330-341.
129. Kilby, J.M.; Lalezari, J.P.; Eron, J.J.; Carlson, M.; Cohen, C.; Arduino, R.C.; Goodgame, J.C.; Gallant, J.E.; Volberding, P.; Murphy, R.L. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retrovir. 2002, 18, 685-693.
130. Desmaële, D.; Gref, R.; Couvreur, P. Squalenoylation: A generic platform for nanoparticular drug delivery. J. Contr. Release 2012, in press, doi:10.1016/j.jconrel.2011.1007.1038.
131. Shah, L.K.; Amiji, M.M. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res. 2006, 23, 2638-2645.
132. Buchanan, C.M.; Buchanan, N.L.; Edgar, K.J.; Little, J.L.; Ramsey, M.G.; Ruble, K.M.; Wacher, V.J.; Wempe, M.F. Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: Hydroxybutenyl-beta-cyclodextrin formulations. Biomacromolecules 2008, 9, 305-313.
133. Sathigari, S.; Chadha, G.; Lee, Y.H.; Wright, N.; Parsons, D.L.; Rangari, V.K.; Fasina, O.; Babu, R.J. Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. AAPS PharmSciTech 2009, 10, 81-87.
134. Wagner, C.R.; Iyer, V.V.; McIntee, E.J. Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 2000, 20, 417-451.
135. Kreuter, J.R.; Täuber, U.; Illi, V. Distribution and elimination of poly (methyl 2 14C methacrylate) nanoparticle radioactivity after injection in rats and mice. J. Pharm. Sci. 1979, 68, 1443-1447.
136. Ahsan, F.; Rivas, I.P.; Khan, M.A.; Torres Suárez, A.I. Targeting to macrophages: Role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Contr. Release 2002, 79, 29-40.
137. Feinberg, M.B. Changing the natural history of HIV disease. Lancet 1996, 348, 239-246.
138. Bestman-Smith, J.; Gourde, P.; Desormeaux, A.; Tremblay, M.J.; Bergeron, M.G. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1. Biochim. Biophys. Acta 2000, 1468, 161-174.
139. Sarin, H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J. Angiogenes. Res. 2010, 2, 1-19.
140. Destache, C.J.; Belgum, T.; Christensen, K.; Shibata, A.; Sharma, A.; Dash, A. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect. Dis. 2009, 9, 198.
141. Lobenberg, R.; Araujo, L.; von Briesen, H.; Rodgers, E.; Kreuter, J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Contr. Release 1998, 50, 21-30.
142. Lobenberg, R.; Kreuter, J. Macrophage targeting of azidothymidine: A promising strategy for AIDS therapy. AIDS Res. Hum. Retroviruses 1996, 12, 1709-1715.
143. Löbenberg, R.; Araujo, L.; Kreuter, J. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur. J. Pharm. Biopharm. 1997, 44, 127-132.
144. Jain, S.; Tiwary, A.K.; Jain, N.K. PEGylated elastic liposomal formulation for lymphatic targeting of zidovudine. Curr. Drug. Deliv. 2008, 5, 275-281.
145. Mainardes, R.M.; Gremião, M.P.D.; Brunetti, I.L.; da Fonseca, L.M.; Khalil, N.M. Zidovudine loaded PLA and PLA-PEG blend nanoparticles: Influence of polymer type on phagocytic uptake by polymorphonuclear cells. J. Pharm. Sci. 2009, 98, 257-267.
146. Batrakova, E.V.; Li, S.; Vinogradov, S.V.; Alakhov, V.Y.; Miller, D.W.; Kabanov, A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: Contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 2001, 299, 483-493.
147. Chattopadhyay, N.; Zastre, J.; Wong, H.L.; Wu, X.Y.; Bendayan, R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res. 2008, 25, 2262-2271.
148. Vyas, T.K.; Shahiwala, A.; Amiji, M.M. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm. 2008, 347, 93-101.
149. Kuo, Y.C.; Chen, H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 2006, 327, 160-169.
150. Kuo, Y.C.; Su, F.L. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int. J. Pharm. 2007, 340, 143-152.
151. Kuo, Y.C.; Kuo, C.Y. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int. J. Pharm. 2008, 351, 271-281.
152. Rao, K.S.; Reddy, M.K.; Horning, J.L.; Labhasetwar, V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008, 29, 4429-4438.
153. McNeil, S.E. Nanotechnology for the biologist. J. Leukoc. Biol. 2005, 78, 585-594.
154. Jabr-Milane, L.; Van Vlerken, L.; Devalapally, H.; Shenoy, D.; Komareddy, S.; Bhavsar, M.; Amiji, M. Multi-functional nanocarriers for targeted delivery of drugs and genes. J. Contr. Release 2008, 130, 121-128.
155. Wan, L.; Zhang, X.; Pooyan, S.; Palombo, M.S.; Leibowitz, M.J.; Stein, S.; Sinko, P.J. Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages. Bioconjug. Chem. 2008, 19, 28-38.
156. Dorman, N.; Lever, A.M. RNA-based gene therapy for HIV infection. HIV Med. 2001, 2, 114-122.
157. Reyes-Darias, J.A.; Sanchez-Luque, F.J.; Berzal-Herranz, A. Inhibition of HIV-1 replication by RNA-based strategies. Curr. HIV Res. 2008, 6, 500-514.
158. McManus, M.T.; Sharp, P.A. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 2002, 3, 737-747.
159. Akhtar, S.; Hughes, M.D.; Khan, A.; Bibby, M.; Hussain, M.; Nawaz, Q.; Double, J.; Sayyed, P. The Delivery of Antisense Therapeutics. Adv. Drug Deliv. Rev. 2000, 44, 3-21.
160. Akhtar, S.; Benter, I. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 2007, 117, 3623-3632.
161. Brown, M.D.; Schatzlein, A.G.; Uchegbu, I.F. Gene delivery with synthetic (non viral) carriers. Int. J. Pharm. 2001, 229, 1-21.
162. Fattal, E.; Bochot, A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int. J. Pharm. 2008, 364, 237-248.
163. Hughes, M.D.; Hussain, M.; Nawaz, Q.; Sayyed, P.; Akhtar, S. The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov. Today 2001, 6, 303-315.
164. Jaaskelainen, I.; Urtti, A. Cell membranes as barriers for the use of antisense therapeutic agents. Mini-Rev. Med. Chem. 2002, 2, 307-318.
165. Juliano, R.; Bauman, J.; Kang, H.; Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 2009, 6, 686-695.
166. Whitehead, K.; Langer, R.; Anderson, D. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8, 129-138.
167. Ozpolat, B.; Sood, A.K.; Lopez-Berestein, G. Nanomedicine based approaches for the delivery of siRNA in cancer. J. Intern. Med. 2010, 267, 44-53.
168. Bordier, B.; Perala-Heape, M.; Degols, G.; Lebleu, B.; Litvak, S.; Sarih-Cottin, L.; Hélène, C. Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: Comparative study in cell-free assays and in HIV-infected cells. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 9383-9387.
169. Dinauer, N.; Lochmann, D.; Demirhan, I.; Bouazzaoui, A.; Zimmer, A.; Chandra, A.; Kreuter, J.; von Briesen, H. Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. J. Contr. Release 2004, 96, 497-507.
170. Mahajan, S.D.; Aalinkeel, R.; Reynolds, J.L.; Nair, B.; Sykes, D.E.; Law, W.C.; Ding, H.; Bergey, E.J.; Prasad, P.N.; Schwartz, S.A. Nanotherapeutics using an HIV-1 Poly A and transactivator of the HIV-1 LTR-(TAR-) specific siRNA. Patholog. Res. Int. 2011, 2011, 719139.
171. Jimenez, J.; Clemente, M.; Weber, N.; Sanchez, J.; Ortega, P.; de Mata, F.; Gomez, R.; Garcia, D.; Lopez-Fernandez, L.; Munoz-Fernandez, M. Carbosilane dendrimers to transfect human astrocytes with small interfering RNA targeting human immunodeficiency virus. BioDrugs 2010, 24, 331-343.
172. Weber, N.; Ortega, P.; Clemente, M.I.; Shcharbin, D.; Bryszewska, M.; de Mata, F.J.; Gomez, R.; Munoz-Fernandez, M.A. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J. Contr. Release 2008, 132, 55-64.
173. Duzgunes, N.; Simoes, S.; Slepushkin, V.; Pretzer, E.; Rossi, J.J.; De Clercq, E.; Antao, V.P.; Collins, M.L.; de Lima, M.C. Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes. Nucleos. Nucleot. Nucleic Acids 2001, 20, 515-523.
174. Konopka, K.; Rossi, J.J.; Swiderski, P.; Slepushkin, V.A.; Duzgunes, N. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim. Biophys. Acta 1998, 1372, 55-68.
175. Kim, S.S.; Peer, D.; Kumar, P.; Subramanya, S.; Wu, H.; Asthana, D.; Habiro, K.; Yang, Y.G.; Manjunath, N.; Shimaoka, M. et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol. Ther. 2010, 18, 370-376.
176. Sun, R.W.; Chen, R.; Chung, N.P.; Ho, C.M.; Lin, C.L.; Che, C.M. Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem. Commun. (Camb.) 2005, 5059-5061.
177. Elechiguerra, J.L.; Burt, J.L.; Morones, J.R.; Camacho-Bragado, A.; Gao, X.; Lara, H.H.; Yacaman, M.J. Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnology 2005, 3, 6.
178. Lara, H.H.; Ayala-Nunez, N.V.; Ixtepan-Turrent, L.; Rodriguez-Padilla, C. Mode of antiviral action of silver nanoparticles against HIV-1. J. Nanobiotechnology 2010, 8, 1.
179. Witvrouw, M.; Fikkert, V.; Pluymers, W.; Matthews, B.; Mardel, K.; Schols, D.; Raff, J.; Debyser, Z.; De Clercq, E.; Holan, G. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol. Pharmacol. 2000, 58, 1100-1108.
180. Macri, R.V.; Karlovska, J.; Doncel, G.F.; Du, X.; Maisuria, B.B.; Williams, A.A.; Sugandhi, E.W.; Falkinham, J.O., 3rd; Esker, A.R.; Gandour, R.D. Comparing anti-HIV, antibacterial, antifungal, micellar, and cytotoxic properties of tricarboxylato dendritic amphiphiles. Bioorg. Med. Chem. 2009, 17, 3162-3168.
181. Blanzat, M.; Turrin, C.O.; Aubertin, A.M.; Couturier-Vidal, C.; Caminade, A.M.; Majoral, J.P.; Rico-Lattes, I.; Lattes, A. Dendritic catanionic assemblies: In vitro anti-HIV activity of phosphorus-containing dendrimers bearing galbeta1cer analogues. Chembiochem 2005, 6, 2207-2213.
182. Han, S.; Yoshida, D.; Kanamoto, T.; Nakashima, H.; Uryu, T.; Yoshida, T. Sulfated oligosaccharide cluster with polylysine core scaffold as a new anti-HIV dendrimer. Carbohyd. Polym. 2010, 80, 1111-1115.
183. Tabarani, G.; Reina, J.J.; Ebel, C.; Vives, C.; Lortat-Jacob, H.; Rojo, J.; Fieschi, F. Mannose hyperbranched dendritic polymers interact with clustered organization of DC-SIGN and inhibit gp120 binding. FEBS Lett. 2006, 580, 2402-2408.
184. Wang, W.; Guo, Z.; Chen, Y.; Liu, T.; Jiang, L. Influence of generation 2-5 of PAMAM dendrimer on the inhibition of Tat peptide/ TAR RNA binding in HIV-1 transcription. Chem. Biol. Drug Des. 2006, 68, 314-318.
185. Rosa Borges, A.; Wieczorek, L.; Johnson, B.; Benesi, A.J.; Brown, B.K.; Kensinger, R.D.; Krebs, F.C.; Wigdahl, B.; Blumenthal, R.; Puri, A. et al. Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1. Virology 2010, 408, 80-88.
186. Yang, D.W.; Ohta, Y.; Yamaguchi, S.; Tsukada, Y.; Haraguchi, Y.; Hoshino, H.; Amagai, H.; Kobayashi, I. Sulfated colominic acid: An antiviral agent that inhibits the human immunodeficiency virus type 1 in vitro. Antivir. Res. 1996, 31, 95-104.
187. Clayton, R.; Hardman, J.; LaBranche, C.C.; McReynolds, K.D. Evaluation of the synthesis of sialic acid-PAMAM glycodendrimers without the use of sugar protecting groups, and the anti-HIV-1 properties of these compounds. Bioconjug. Chem. 2011, 22, 2186-2197.
188. Schinazi, R.F.; Brettreich, M.; Hirsch, A. Water-soluble dendrimeric fullerene as anti-HIV therapeutic. US Patent App. 20,030/036,562: 2001.
189. Friedman, S.H.; Decamp, D.L.; Sijbesma, R.P.; Srdanov, G.; Wudl, F.; Kenyon, G.L. Inhibition of the HIV-1 protease by fullerene derivatives-Model-building studies and experimental-verification. J. Am. Chem. Soc. 1993, 115, 6506-6509.
190. Weislow, O.S.; Kiser, R.; Fine, D.L.; Bader, J.; Shoemaker, R.H.; Boyd, M.R. New solubleformazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer I. 1989, 81, 577-586.
191. European Medicines Agency Scientific Discussion for the Approval of Kaletra. Available online: http://www.ema.europa.eu (accessed on 31 October 2011)
192. Li, M.; Al-Jamal, K.T.; Kostarelos, K.; Reineke, J. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano 2010, 4, 6303-6317.
193. Ochekpe, N.A.; Olorunfemi, P.O.; Ngwuluka, N.C. Nanotechnology and drug delivery part 2: Nanostructures for drug delivery. Trop. J. Pharm. Res. 2009, 8, 275-287.
194. European Medicines Agency 1st International Workshop on Nanomedicines 2010 Summary Report. Available online: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001108.jsp&murl=menus/news_and_events/news_and_events.jsp&m id=WC0b01ac058004d5c1 (accessed on 12 March 2012).